Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA® (pembrolizumab)1, 2
SANTA CLARA, Calif., March 26
Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. Read more
